NanoViricides is trading 5.43% higher at $1.36 on November 6, 2026, with the move supported by a biotech-sector lift rather than a company-specific catalyst. - XBI is up 2.01%; supplied market context attributes the rally to Moderna’s results and raised outlook. - No fresh company-specific announcement was identified. NanoViricides’ latest update, on October 27, said its Phase IIA Ebola trial was progressing and it anticipated advancing to Phase IIB after completion.